Home > Insider Trading > Filing (0001179110-21-003441)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1709401	Rubius Therapeutics Inc.	RUBY	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1693805	Maiken Keson-Brookes	C/O Rubius Therapeutics, Inc. 399 Binney Street, Suite 300 Cambridge MA 02139	Clo & Corp. Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-03-15	25,000	$7.70	25,000	No	4	M	Direct
Common Stock	Disposition	2021-03-15	25,000	$20.24	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-15	25,000	$0.00	25,000	$7.70

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
225,000		2029-11-28	No	4	M	Direct

Footnotes

The sale was effected pursuant to a Rule 10b5-1 trading plan, effective January 15, 2020, adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.69, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
25% of this option vested on November 18, 2020, then in 12 equal quarterly installments thereafter.